FILE PHOTO: Sanofi logo at the company’s headquarters during the annual press conference in Paris, France, February 4, 2022. REUTERS/Benoit Tessier
March 29, 2022
PARIS (Reuters) – French healthcare group Sanofi, which has been lagging behind rivals in the COVID-19 vaccine race, on Tuesday raised its peak sales target for eczema treatment product Dupixent to more than 13 billion euros ($14.3 billion).
“This new target does not include the potential for an additional increase in the chronic obstructive pulmonary disease (COPD) revenue target, with key metrics expected in 2023,” Sanofi said in a statement.
Earlier this month, analysts at investment bank JP Morgan said they expected Sanofi to raise its peak sales forecast for Dupixent to about $15 billion.
Sanofi is working with UK partner GlaxoSmithKline to develop a COVID-19 vaccine.
Sanofi also announced Tuesday a partnership with US company IGM Biosciences in the field of oncology, immunology and inflammation treatments.
(Reporting by Sudip Kar-Gupta; Editing by Clarence Fernandez and Jacqueline Wong)
https://www.oann.com/healthcare-group-sanofi-targets-dupixent-peak-sales-of-over-13-billion-euros/?utm_source=rss&utm_medium=rss&utm_campaign=healthcare-group-sanofi-targets-dupixent-peak-sales-of-over-13-billion-euros With Dupixent, Sanofi is aiming for a peak turnover of over 13 billion euros